newsfilter
← Latest News
GlobeNewswire·

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data demonstrating